<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn fn-type="COI-statement">
  <p>Competing interest statement: The authors affiliated with Gilead Sciences are employees of the company and may own company stock; R.J. holds a patent on the use of remdesivir to treat Filovirus infections. The authors affiliated with NIH have no conflict of interest to report.</p>
 </fn>
 <fn fn-type="other">
  <p>This article is a PNAS Direct Submission.</p>
 </fn>
 <fn fn-type="other">
  <p>Data deposition: All data discussed here will be made available to readers upon request.</p>
 </fn>
 <fn fn-type="supplementary-material">
  <p>This article contains supporting information online at 
   <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1922083117/-/DCSupplemental" xlink:show="new" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1922083117/-/DCSupplemental</ext-link>.
  </p>
 </fn>
</fn-group>
